Cargando…
Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
Historically, there have been few treatment options for patients with advanced renal cell carcinoma (RCC) besides immunotherapy with interleukin-2 and interferon (IFN)-α. Targeted therapies have improved clinical outcomes over the past several years. These include the vascular endothelial growth fac...
Autores principales: | Agarwala, Sanjiv S., Case, Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227953/ https://www.ncbi.nlm.nih.gov/pubmed/20215359 http://dx.doi.org/10.1634/theoncologist.2009-0141 |
Ejemplares similares
-
Fatigue in Renal Cell Carcinoma: The Hidden Burden of Current Targeted Therapies
por: Larkin, James M.G., et al.
Publicado: (2010) -
Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents
por: Moxley, Katherine M., et al.
Publicado: (2010) -
Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction
por: Wang, Tzu-Fei, et al.
Publicado: (2023) -
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
por: Garbe, Claus, et al.
Publicado: (2011) -
Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
por: Cameron, David, et al.
Publicado: (2010)